A number of firms have modified their ratings and price targets on shares of STAAR Surgical (NASDAQ: STAA) recently:

  • 10/11/2017 – STAAR Surgical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. “
  • 10/8/2017 – STAAR Surgical had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $15.00 price target on the stock.
  • 9/25/2017 – STAAR Surgical was upgraded by analysts at Canaccord Genuity from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock.
  • 9/23/2017 – STAAR Surgical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $12.00 price target on the stock. According to Zacks, “Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. “
  • 9/22/2017 – STAAR Surgical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. “
  • 9/6/2017 – STAAR Surgical had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $11.00 price target on the stock.
  • 8/19/2017 – STAAR Surgical was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/15/2017 – STAAR Surgical was upgraded by analysts at TheStreet from a “d+” rating to a “c” rating.
  • 8/14/2017 – STAAR Surgical had its price target raised by analysts at Benchmark Co. from $12.00 to $13.00. They now have a “buy” rating on the stock.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.04. STAAR Surgical had a negative return on equity of 8.69% and a negative net margin of 6.06%. The company had revenue of $21.90 million for the quarter, compared to analysts’ expectations of $22.15 million. During the same period last year, the firm earned ($0.02) EPS. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis.

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with MarketBeat.com's FREE daily email newsletter.